利索-全球专利检索

  1. Login
  2. Sign Up
Invention Publication
CN105884895A 抗人CCR7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体 有权 转让

抗人CCR7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
Abstract:
本发明的课题在于提供作为组织的纤维化或癌的治疗药有用的新型的抗人CCR7抗体、以及含有该抗人CCR7抗体的医药组合物等。提供一种抗人CCR7抗体，其为与人CCR7的细胞外结构域特异性结合的抗人CCR7抗体，具有包含序列编号7、17、27、37、47、57、67或77所示的氨基酸序列的重链CDR3。还提供一种具有包含序列编号5～10、15～20、25～30、35～40、45～50、55～60、65～70或75～80所示的氨基酸序列的重链CDR1～3和轻链CDR1～3的抗人CCR7抗体。优选具有阻断通过刺激CCR7配体而产生的CCR7依赖性细胞内信号传导机制的活性。本发明的抗人CCR7抗体能够作为组织的纤维化或癌的治疗药的有效成分使用。
Abstract(English):

An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.

Public/Granted literature
Patent Agency Ranking
0/0